These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15316429)

  • 1. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
    Nijkeuter M; Huisman MV
    Curr Opin Pulm Med; 2004 Sep; 10(5):338-44. PubMed ID: 15316429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
    Turpie AG; Bauer KA; Eriksson BI; Lassen MR
    Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
    Reynolds NA; Perry CM; Scott LJ
    Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG
    Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
    Turpie AG; Eriksson BI; Bauer KA; Lassen MR
    Chest; 2003 Dec; 124(6 Suppl):371S-378S. PubMed ID: 14668420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of venous thromboembolism after major orthopedic surgery: update and contribution of a specific synthetic inhibitor of factor Xa].
    Samama MM
    Rev Chir Orthop Reparatrice Appar Mot; 2003 Dec; 89(8):712-24. PubMed ID: 14726838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux, the first selective factor Xa inhibitor.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    Curr Opin Hematol; 2003 Sep; 10(5):327-32. PubMed ID: 12913785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
    Comp PC
    Pharmacotherapy; 2003 Jun; 23(6):772-87. PubMed ID: 12820819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery.
    Bergqvist D
    Vasc Health Risk Manag; 2006; 2(4):365-70. PubMed ID: 17323590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG;
    N Engl J Med; 2001 Nov; 345(18):1305-10. PubMed ID: 11794149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentasaccharides.
    Turpie AG
    Semin Hematol; 2002 Jul; 39(3):158-71. PubMed ID: 12124678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.
    Turpie AG; Bauer KA; Eriksson BI; Lassen MR
    Chest; 2004 Aug; 126(2):501-8. PubMed ID: 15302737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
    Turpie AG
    Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
    Turpie AG
    Int J Clin Pract; 2004 May; 58(5):483-93. PubMed ID: 15206506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.
    Lobo BL
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):66S-72S. PubMed ID: 15317401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-acting synthetic pentasaccharides.
    Koopman MM; Büller HR
    J Intern Med; 2003 Oct; 254(4):335-42. PubMed ID: 12974872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Apr; 3(4):455-7. PubMed ID: 11934350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.